Intrathecal sICAM-1 production in multiple sclerosis--correlation with triple dose Gd-DTPA MRI enhancement and IgG index.
In this study the aim was to evaluate the intrathecal sICAM-1 production in multiple sclerosis (MS) patients during relapse and remission. In addition to this, we assessed whether there is a correlation between intrathecal sICAM-1 production and other disease activity markers such as IgG index and gadolinium enhancement in magnetic resonance imaging (MRI). Twenty four relapsing-remitting MS patients were included in the study. Serum and cerebrospinal fluid (CSF) samples were obtained both during relapse and remission. The soluble form of ICAM (sICAM) was measured by the ELISA method in serum and CSF. Cranial MRI with triple dose gadolinium injection was performed for each patient both during relapse and remission. Serum levels of sICAM-1 (245.23 +/- 92.88 ng/ml) were higher during relapse than those in remission (219.90 +/- 110.94 ng/ml), but the difference was not statistically significant. In relapse periods CSF levels of sICAM-1 (1.304 +/- 0.92 ng/ml) were higher than those in remission (1.06 +/- 0.86 ng/ml), but this was not significant. However, during relapse periods patients had significantly higher sICAM-1 index values (1.76 +/- 0.60) than those found during remission periods (1.01 +/- 0.44) (p < 0.05). The IgG index values were higher in relapse periods than in remission (0.88 +/- 0.37 vs. 0.67 +/- 0.28) (p < 0.005). On T1 weighted images following triple dose Gd injection, at least two or more enhancing lesions were present in 22/24 of the patients (91%) in relapse and 4/24 of the patients (19%) in remission. There was strong correlation both between the sICAM-1 index and Gd enhancement (r =0 .72 p < 0.05) and sICAM-1 index and IgG index in relapse (r = 0.69 p < 0.05). In conclusion, there is association between high sICAM-1 and IgG indices, as well as between high sICAM-1 index and Gd enhancing MRI lesions in relapsing MS patients.
Acar
Göksemin
G
Karşiyaka Neurology Outpatient Clinic, Dokuz Eylül University, Izmir, Turkey. goksemind@yahoo.com
Idiman
Fethi
F
Kirkali
Güldal
G
Ozakbaş
Serkan
S
Oktay
Gülgün
G
Cakmakçi
Handan
H
Idiman
Egemen
E
D000328:Adult; D018450:Disease Progression; D004797:Enzyme-Linked Immunosorbent Assay / Q000379:methods; D005260:Female; D019786:Gadolinium DTPA; D006801:Humans; D007089:Image Enhancement / Q000379:methods; D007074:Immunoglobulin G / Q000378:metabolism*; D047468:Immunoprecipitation / Q000379:methods; D018799:Intercellular Adhesion Molecule-1 / Q000097:blood* / Q000134:cerebrospinal fluid*; D008279:Magnetic Resonance Imaging; D008297:Male; D009103:Multiple Sclerosis / Q000097:blood* / Q000134:cerebrospinal fluid*; D009391:Nephelometry and Turbidimetry / Q000379:methods; D012995:Solubility; D013223:Statistics as Topic / Q000379:methods; D018709:Statistics, Nonparametric; D013997:Time Factors
D007074:Immunoglobulin G; D018799:Intercellular Adhesion Molecule-1; D019786:Gadolinium DTPA
Neurology. 1993 Sep;43(9):1809-13
8105425
Ann Neurol. 1995 Jan;37(1):55-62
7529475
J Neuroimmunol. 1998 May 15;85(2):186-92
9630167
Neurology. 1996 Dec;47(6):1535-41
8960741
Annu Rev Immunol. 1993;11:767-804
8476577
Ann Neurol. 2001 Jul;50(1):121-7
11456302
Neurology. 1993 Nov;43(11):2331-5
7901809
Immunol Today. 1993 Oct;14(10):506-12
7506035
Ann Neurol. 1995 Aug;38(2):186-93
7544573
J Neuroimmunol. 1996 Feb;64(2):185-91
8632061
J Neuroimmunol. 1998 Aug 1;88(1-2):120-7
9688333
Invasion Metastasis. 1992;12(2):66-81
1383172
Neurology. 1997 Jun;48(6):1557-65
9191766
Ann Neurol. 1993 Jun;33(6):646-9
8098933
Ann Neurol. 1997 Mar;41(3):326-33
9066353
Neurology. 1983 Nov;33(11):1444-52
6685237
J Neuroimmunol. 1993 Mar;43(1-2):15-21
8096220
Neurology. 1994 Dec;44(12):2367-72
7527508